companydata.dkSYNACT PHARMA ApS: Financial statements 2016
CVR: 34459975
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK -9,884,650 and a net result of DKK -8,884,785 compared with DKK -782,555 the year before. Equity amounted to DKK 9,925,326. The solvency ratio was 46.7%.
- Gross Profit
- -9,884,650 kr.
- Profit/Loss
- -8,884,785 kr.
- Equity
- 9,925,326 kr.
- Total Assets
- 21,259,875 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | -9.9 mio. | -8.9 mio. | 9.9 mio. | - |
| 2015 | - | -309 t. | -783 t. | -3.9 mio. | - |
| 2014 | - | -343 t. | -768 t. | -3.1 mio. | - |
| 2013 | - | -953 t. | -1.1 mio. | -2.3 mio. | - |
How creditworthy is SYNACT PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2016
As of April 12, 2016, is registered as an owner of SYNACT PHARMA ApS with an ownership share of 100%.
SYNACT PHARMA ApS has published its annual report for 2015. Gross profit came to DKK -309,046, and the net result was DKK -782,555.
As of March 17, 2016, Forvis Mazars Statsautoriseret Revisionspartnerselskab has been appointed auditor of SYNACT PHARMA ApS.
As of March 17, 2016, DANSK REVISION MARIAGERFJORD, STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of SYNACT PHARMA ApS.
As of March 10, 2016, Otto Bjerg Hausgaard has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Sigbjørn Georg Nielsen Kjærgård has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Thomas Engelbrecht Nordkild Jonassen has left the board of directors of SYNACT PHARMA ApS.
As of March 10, 2016, Henrik Stage is registered as director of SYNACT PHARMA ApS.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.